세계의 다중 암 조기 발견 시장 - 업계 분석, 규모, 점유율, 성장, 동향, 지역별 전망 및 예측(2023-2030년) : 유형별, 최종 용도별, 지역별, 기업별

Multi-Cancer Early Detection Market - Global Multi-cancer Early Detection Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023-2030 - (By Type Coverage, By End User Coverage, By Geographic Coverage and By Company)

US $ 4,995 ￦ 7,227,000

Unprintable PDF & Excel (Single User License)

PDF 및 Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며 텍스트의 Copy&Paste도 불가능합니다.

US $ 8,495 ￦ 12,291,000

Unprintable PDF & Excel (Multi User License upto 5 users)

PDF 및 Excel 보고서를 동일 사업장에서 5명까지 이용할 수 있는 라이선스입니다. 텍스트는 Copy & Paste 가능하지만, 인쇄는 불가능합니다.

US $ 10,600 ￦ 15,337,000

Printable PDF & Excel (Enterprise License above 5 users)

PDF 및 Excel 보고서를 동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용자수는 5명 이상이며 제한은 없습니다. Copy & Paste 및 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

세계의 다중 암 조기 발견(MCED) 시장 규모는 크게 확대되는 기세이며, 2023년부터 2030년까지 CAGR 16.3%가 될 것으로 예측되고 있습니다. 이 시장은 2022년 약 8억 9,000만 달러에서 2030년 말까지 약 25억 달러까지 확대될 것으로 예측됩니다.

MCED 시장은 암 이환율 증가나 암의 조기 발견에 중점을 둔 정부의 대처 등 요인별로 확대될 것으로 보입니다. 다양한 암의 징후를 정확하고 동시에 검색할 수 있는 검사의 개척이 시장 성장을 가속할 것으로 예측됩니다. 이러한 검사는 많은 유형의 암에 대한 효율적인 스크리닝 접근법의 부족을 해결합니다.

환자의 생존율을 높이고 치료비를 삭감하기 위한 조기암 발견의 이점에 대한 인식 증가가 시장의 가능성을 뒷받침하고 있습니다. 2022년에는 유전자 패널 카테고리가 MCED 시장을 독점했습니다. 유전자 패널은 다양한 악성 종양과 관련된 여러 유전자의 표적 연구를 제공하여 정확한 위험 평가와 조기 발견을 가능하게 합니다.

이 보고서는 세계의 다중 암 조기 발견 시장에 대해 조사했으며, 시장 개요와 함께 유형별, 최종 용도별, 지역별 동향 및 시장 진출기업의 경쟁 동향 등을 제공합니다.

목차

제1장 주요 요약

제2장 시장 개요

• 시장 정의 및 세분화
• 시장 역학
• 밸류체인 분석
• Porter's Five Forces 분석
• COVID-19의 영향 분석
• 우크라이나와 러시아의 분쟁의 영향
• 경제 개요
• PESTLE 분석

제3장 세계의 다중 암 조기 발견 시장 전망(2018-2030년)

• 세계의 다중 암 조기 발견 시장 전망 : 유형별, 금액별(10억 달러)(2018-2030년)
• 세계의 다중 암 조기 발견 시장 전망 : 최종 용도별, 금액(10억 달러)(2018-2030년)
• 세계의 다중 암 조기 발견 시장 전망 : 지역별, 금액(10억 달러)(2018-2030년)

제4장 북미의 다중 암 조기 발견 시장 전망(2018-2030년)

제5장 유럽의 다중 암 조기 발견 시장 전망(2018-2030년)

제6장 아시아태평양의 다중 암 조기 발견 시장 전망(2018-2030년)

제7장 라틴아메리카의 다중 암 조기 발견 시장 전망(2018-2030년)

제8장 중동 및 아프리카의 다중 암 조기 발견 시장 전망(2018-2030년)

제9장 경쟁 구도

• 능력 및 용도의 히트 맵
• 제조업체 및 용도의 히트 맵
• 기업의 시장 점유율 분석(2022년)
• 경쟁력 대시보드
• 기업 프로파일
  • Grail, LLC
  • Illumina, Inc.
  • Exact Sciences Corporation
  • Foundation Medicine
  • AnchorDx
  • Guardant Health, Inc.
  • Burning Rock Biotech Limited
  • GENECAST
  • Laboratory for Advanced Medicine, Inc
  • Singlera Genomics Inc
  • Elypta
  • Prenetics Global Limited(Prenetics)
  • Oncocyte Corporation
  • Micronoma Inc
  • EarlyDiagnostics, Inc

제10장 부록

AJY

영문 목차

영문목차

The global multi-cancer early detection (MCED) market is on the verge of substantial expansion, with Fairfield Market Research projecting a notable CAGR of 16.3% between 2023 and 2030. The market, which reached a valuation of approximately $0.89 billion in 2022, is anticipated to soar to around $2.5 billion by the end of 2030.

Key Market Trends

• 1. Rising Incidence of Cancer and Government Emphasis: The MCED market is set to expand due to factors such as the increasing incidence of cancer and government initiatives focusing on early cancer detection.
• 2. Development of Precise Tests: The development of tests that can precisely and simultaneously search for signs of various cancers is projected to fuel market growth. These tests address the lack of efficient screening approaches for many types of cancer.
• 3. Growing Awareness: Increased awareness of the benefits of early cancer detection for enhancing patient survival and lowering treatment costs is driving market potential.
• 4. Gene Panels Dominate: In 2022, the gene panel category dominated the MCED market. Gene panels enable precise risk assessment and early detection by offering targeted studies of multiple genes associated with various malignancies.

Key Growth Determinants

Exploding Cancer Prevalence: The growing prevalence of cancer is a major driver of market demand. Chronic diseases like cancer disproportionately affect the elderly population, particularly in high-income countries. The market is expected to rise as the elderly population increases.

Awareness Initiatives: Rising government initiatives to increase public awareness of the benefits of early diagnosis will drive market growth for MCED. These initiatives aim to educate people about the need for early diagnosis, leading to increased demand for multi-cancer screening tests.

Benefits of Early Detection: Early cancer detection results in better treatment outcomes, lower healthcare expenditures, and higher patient survival rates. Prompt intervention and specialized therapy made possible by early diagnosis lead to better patient outcomes, encouraging investment in MCED technologies.

Major Barriers

High Diagnostic System Costs: High costs of diagnostic devices, stringent regulatory regulations, and lengthy clearance processes for new launches hinder global MCED market growth.

Adoption of Refurbished Imaging Systems: Hospitals in poorer countries, unable to invest in new diagnostic imaging technology, often opt for refurbished systems. These systems are more affordable than new ones, impacting market growth.

Regional Highlights

Europe Leads in Revenue Contribution: Europe's dominance is due to rising cancer incidence and increased investment in research and development. The region's expanding population, vulnerability to chronic diseases, and economic diagnosis in rural areas support market expansion.

North America Shows Fastest Growth: North America is expected to experience the fastest growth due to government and market participant activities. The region's expanding cancer incidence and significant trials further boost market growth.

Competitive Landscape Analysis

The global MCED market is consolidated, with a few significant companies operating worldwide. Major firms are launching new products and expanding their distribution networks to increase their global presence. Market consolidation is expected to continue in the coming years.

Leaders in Global Multi-Cancer Early Detection Space

• 1. Grail, Llc
• 2. Illumina, Inc.
• 3. Exact Sciences Corporation
• 4. Foundation Medicine, Inc.
• 5. AnchorDx
• 6. Guardant Health, Inc.
• 7. Burning Rock Biotech Limited
• 8. GENECAST
• 9. Laboratory for Advanced Medicine, Inc.

10. Singlera Genomics Inc.

11. Elypta

12. Prenetics Global Limited (Prenetics)

13. Oncocyte Corporation

14. Micronoma Inc.

15. EarlyDiagnostics, Inc.

Global Multi Cancer Early Detection Market is Segmented as Below:

By Type:

• Liquid Biopsy
• Gene Panel
• LDT
• Others

By End User:

• Hospitals
• Diagnostic Laboratories
• Others

By Geographic Coverage:

• North America

U.S.

Canada

• Europe

Germany

U.K.

France

Italy

Turkey

Russia

Rest of Europe

• Asia Pacific

China

Japan

South Korea

India

Southeast Asia

Rest of Asia Pacific

• Latin America

Brazil

Mexico

Argentina

Rest of Latin America

• Middle East & Africa

GCC

South Africa

Egypt

Nigeria

Rest of Middle East & Africa

Table of Contents

1. Executive Summary

• 1.1. Global Multi Cancer Early Detection Market Snapshot
• 1.2. Future Projections
• 1.3. Key Market Trends
• 1.4. Regional Snapshot, by Value, 2022
• 1.5. Analyst Recommendations

2. Market Overview

• 2.1. Market Definitions and Segmentations
• 2.2. Market Dynamics
  • 2.2.1. Drivers
  • 2.2.2. Restraints
  • 2.2.3. Market Opportunities
• 2.3. Value Chain Analysis
• 2.4. Porter's Five Forces Analysis
• 2.5. COVID-19 Impact Analysis
  • 2.5.1. Supply
  • 2.5.2. Demand
• 2.6. Impact of Ukraine-Russia Conflict
• 2.7. Economic Overview
  • 2.7.1. World Economic Projections
• 2.8. PESTLE Analysis

3. Global Multi Cancer Early Detection Market Outlook, 2018 - 2030

• 3.1. Global Multi Cancer Early Detection Market Outlook, by Type, Value (US$ Bn), 2018 - 2030
  • 3.1.1. Key Highlights
    • 3.1.1.1. Liquid Biopsy
    • 3.1.1.2. Gene Panel
    • 3.1.1.3. LDT
    • 3.1.1.4. Others
• 3.2. Global Multi Cancer Early Detection Market Outlook, by End Use, Value (US$ Bn), 2018 - 2030
  • 3.2.1. Key Highlights
    • 3.2.1.1. Hospitals
    • 3.2.1.2. Diagnostic Laboratories
    • 3.2.1.3. Others
• 3.3. Global Multi Cancer Early Detection Market Outlook, by Region, Value (US$ Bn), 2018 - 2030
  • 3.3.1. Key Highlights
    • 3.3.1.1. North America
    • 3.3.1.2. Europe
    • 3.3.1.3. Asia Pacific
    • 3.3.1.4. Latin America
    • 3.3.1.5. Middle East & Africa

4. North America Multi Cancer Early Detection Market Outlook, 2018 - 2030

• 4.1. North America Multi Cancer Early Detection Market Outlook, by Type, Value (US$ Bn), 2018 - 2030
  • 4.1.1. Key Highlights
    • 4.1.1.1. Liquid Biopsy
    • 4.1.1.2. Gene Panel
    • 4.1.1.3. LDT
    • 4.1.1.4. Others
• 4.2. North America Multi Cancer Early Detection Market Outlook, by End Use, Value (US$ Bn), 2018 - 2030
  • 4.2.1. Key Highlights
    • 4.2.1.1. Hospitals
    • 4.2.1.2. Diagnostic Laboratories
    • 4.2.1.3. Others
  • 4.2.2. BPS Analysis/Market Attractiveness Analysis
• 4.3. North America Multi Cancer Early Detection Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
  • 4.3.1. Key Highlights
    • 4.3.1.1. U.S. Multi Cancer Early Detection Market by Type, Value (US$ Bn), 2018 - 2030
    • 4.3.1.2. U.S. Multi Cancer Early Detection Market by End Use, Value (US$ Bn), 2018 - 2030
    • 4.3.1.3. Canada Multi Cancer Early Detection Market by Type, Value (US$ Bn), 2018 - 2030
    • 4.3.1.4. Canada Multi Cancer Early Detection Market by End Use, Value (US$ Bn), 2018 - 2030
  • 4.3.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Multi Cancer Early Detection Market Outlook, 2018 - 2030

• 5.1. Europe Multi Cancer Early Detection Market Outlook, by Type, Value (US$ Bn), 2018 - 2030
  • 5.1.1. Key Highlights
    • 5.1.1.1. Liquid Biopsy
    • 5.1.1.2. Gene Panel
    • 5.1.1.3. LDT
    • 5.1.1.4. Others
• 5.2. Europe Multi Cancer Early Detection Market Outlook, by End Use, Value (US$ Bn), 2018 - 2030
  • 5.2.1. Key Highlights
    • 5.2.1.1. Hospitals
    • 5.2.1.2. Diagnostic Laboratories
    • 5.2.1.3. Others
  • 5.2.2. BPS Analysis/Market Attractiveness Analysis
• 5.3. Europe Multi Cancer Early Detection Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
  • 5.3.1. Key Highlights
    • 5.3.1.1. Germany Multi Cancer Early Detection Market by Type, Value (US$ Bn), 2018 - 2030
    • 5.3.1.2. Germany Multi Cancer Early Detection Market by End Use, Value (US$ Bn), 2018 - 2030
    • 5.3.1.3. U.K. Multi Cancer Early Detection Market by Type, Value (US$ Bn), 2018 - 2030
    • 5.3.1.4. U.K. Multi Cancer Early Detection Market by End Use, Value (US$ Bn), 2018 - 2030
    • 5.3.1.5. France Multi Cancer Early Detection Market by Type, Value (US$ Bn), 2018 - 2030
    • 5.3.1.6. France Multi Cancer Early Detection Market by End Use, Value (US$ Bn), 2018 - 2030
    • 5.3.1.7. Italy Multi Cancer Early Detection Market by Type, Value (US$ Bn), 2018 - 2030
    • 5.3.1.8. Italy Multi Cancer Early Detection Market by End Use, Value (US$ Bn), 2018 - 2030
    • 5.3.1.9. Turkey Multi Cancer Early Detection Market by Type, Value (US$ Bn), 2018 - 2030
    • 5.3.1.10. Turkey Multi Cancer Early Detection Market by End Use, Value (US$ Bn), 2018 - 2030
    • 5.3.1.11. Russia Multi Cancer Early Detection Market by Type, Value (US$ Bn), 2018 - 2030
    • 5.3.1.12. Russia Multi Cancer Early Detection Market by End Use, Value (US$ Bn), 2018 - 2030
    • 5.3.1.13. Rest of Europe Multi Cancer Early Detection Market by Type, Value (US$ Bn), 2018 - 2030
    • 5.3.1.14. Rest of Europe Multi Cancer Early Detection Market by End Use, Value (US$ Bn), 2018 - 2030
  • 5.3.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Multi Cancer Early Detection Market Outlook, 2018 - 2030

• 6.1. Asia Pacific Multi Cancer Early Detection Market Outlook, by Type, Value (US$ Bn), 2018 - 2030
  • 6.1.1. Key Highlights
    • 6.1.1.1. Liquid Biopsy
    • 6.1.1.2. Gene Panel
    • 6.1.1.3. LDT
    • 6.1.1.4. Others
• 6.2. Asia Pacific Multi Cancer Early Detection Market Outlook, by End Use, Value (US$ Bn), 2018 - 2030
  • 6.2.1. Key Highlights
    • 6.2.1.1. Hospitals
    • 6.2.1.2. Diagnostic Laboratories
    • 6.2.1.3. Others
  • 6.2.2. BPS Analysis/Market Attractiveness Analysis
• 6.3. Asia Pacific Multi Cancer Early Detection Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
  • 6.3.1. Key Highlights
    • 6.3.1.1. China Multi Cancer Early Detection Market by Type, Value (US$ Bn), 2018 - 2030
    • 6.3.1.2. China Multi Cancer Early Detection Market by End Use, Value (US$ Bn), 2018 - 2030
    • 6.3.1.3. Japan Multi Cancer Early Detection Market by Type, Value (US$ Bn), 2018 - 2030
    • 6.3.1.4. Japan Multi Cancer Early Detection Market by End Use, Value (US$ Bn), 2018 - 2030
    • 6.3.1.5. South Korea Multi Cancer Early Detection Market by Type, Value (US$ Bn), 2018 - 2030
    • 6.3.1.6. South Korea Multi Cancer Early Detection Market by End Use, Value (US$ Bn), 2018 - 2030
    • 6.3.1.7. India Multi Cancer Early Detection Market by Type, Value (US$ Bn), 2018 - 2030
    • 6.3.1.8. India Multi Cancer Early Detection Market by End Use, Value (US$ Bn), 2018 - 2030
    • 6.3.1.9. Southeast Asia Multi Cancer Early Detection Market by Type, Value (US$ Bn), 2018 - 2030
    • 6.3.1.10. Southeast Asia Multi Cancer Early Detection Market by End Use, Value (US$ Bn), 2018 - 2030
    • 6.3.1.11. Rest of Asia Pacific Multi Cancer Early Detection Market by Type, Value (US$ Bn), 2018 - 2030
    • 6.3.1.12. Rest of Asia Pacific Multi Cancer Early Detection Market by End Use, Value (US$ Bn), 2018 - 2030
  • 6.3.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Multi Cancer Early Detection Market Outlook, 2018 - 2030

• 7.1. Latin America Multi Cancer Early Detection Market Outlook, by Type, Value (US$ Bn), 2018 - 2030
  • 7.1.1. Key Highlights
    • 7.1.1.1. Liquid Biopsy
    • 7.1.1.2. Gene Panel
    • 7.1.1.3. LDT
    • 7.1.1.4. Others
• 7.2. Latin America Multi Cancer Early Detection Market Outlook, by End Use, Value (US$ Bn), 2018 - 2030
  • 7.2.1. Key Highlights
    • 7.2.1.1. Hospitals
    • 7.2.1.2. Diagnostic Laboratories
    • 7.2.1.3. Others
  • 7.2.2. BPS Analysis/Market Attractiveness Analysis
• 7.3. Latin America Multi Cancer Early Detection Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
  • 7.3.1. Key Highlights
    • 7.3.1.1. Brazil Multi Cancer Early Detection Market by Type, Value (US$ Bn), 2018 - 2030
    • 7.3.1.2. Brazil Multi Cancer Early Detection Market by End Use, Value (US$ Bn), 2018 - 2030
    • 7.3.1.3. Mexico Multi Cancer Early Detection Market by Type, Value (US$ Bn), 2018 - 2030
    • 7.3.1.4. Mexico Multi Cancer Early Detection Market by End Use, Value (US$ Bn), 2018 - 2030
    • 7.3.1.5. Argentina Multi Cancer Early Detection Market by Type, Value (US$ Bn), 2018 - 2030
    • 7.3.1.6. Argentina Multi Cancer Early Detection Market by End Use, Value (US$ Bn), 2018 - 2030
    • 7.3.1.7. Rest of Latin America Multi Cancer Early Detection Market by Type, Value (US$ Bn), 2018 - 2030
    • 7.3.1.8. Rest of Latin America Multi Cancer Early Detection Market by End Use, Value (US$ Bn), 2018 - 2030
  • 7.3.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Multi Cancer Early Detection Market Outlook, 2018 - 2030

• 8.1. Middle East & Africa Multi Cancer Early Detection Market Outlook, by Type, Value (US$ Bn), 2018 - 2030
  • 8.1.1. Key Highlights
    • 8.1.1.1. Liquid Biopsy
    • 8.1.1.2. Gene Panel
    • 8.1.1.3. LDT
    • 8.1.1.4. Others
• 8.2. Middle East & Africa Multi Cancer Early Detection Market Outlook, by End Use, Value (US$ Bn), 2018 - 2030
  • 8.2.1. Key Highlights
    • 8.2.1.1. Hospitals
    • 8.2.1.2. Diagnostic Laboratories
    • 8.2.1.3. Others
  • 8.2.2. BPS Analysis/Market Attractiveness Analysis
• 8.3. Middle East & Africa Multi Cancer Early Detection Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
  • 8.3.1. Key Highlights
    • 8.3.1.1. GCC Multi Cancer Early Detection Market by Type, Value (US$ Bn), 2018 - 2030
    • 8.3.1.2. GCC Multi Cancer Early Detection Market by End Use, Value (US$ Bn), 2018 - 2030
    • 8.3.1.3. South Africa Multi Cancer Early Detection Market by Type, Value (US$ Bn), 2018 - 2030
    • 8.3.1.4. South Africa Multi Cancer Early Detection Market by End Use, Value (US$ Bn), 2018 - 2030
    • 8.3.1.5. Egypt Multi Cancer Early Detection Market by Type, Value (US$ Bn), 2018 - 2030
    • 8.3.1.6. Egypt Multi Cancer Early Detection Market by End Use, Value (US$ Bn), 2018 - 2030
    • 8.3.1.7. Nigeria Multi Cancer Early Detection Market by Type, Value (US$ Bn), 2018 - 2030
    • 8.3.1.8. Nigeria Multi Cancer Early Detection Market by End Use, Value (US$ Bn), 2018 - 2030
    • 8.3.1.9. Rest of Middle East & Africa Multi Cancer Early Detection Market by Type, Value (US$ Bn), 2018 - 2030
    • 8.3.1.10. Rest of Middle East & Africa Multi Cancer Early Detection Market by End Use, Value (US$ Bn), 2018 - 2030
  • 8.3.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

• 9.1. Capacity vs Application Heatmap
• 9.2. Manufacturer vs Application Heatmap
• 9.3. Company Market Share Analysis, 2022
• 9.4. Competitive Dashboard
• 9.5. Company Profiles
  • 9.5.1. Grail, LLC
    • 9.5.1.1. Company Overview
    • 9.5.1.2. Product Portfolio
    • 9.5.1.3. Financial Overview
    • 9.5.1.4. Business Strategies and Development
  • 9.5.2. Illumina, Inc.
    • 9.5.2.1. Company Overview
    • 9.5.2.2. Product Portfolio
    • 9.5.2.3. Financial Overview
    • 9.5.2.4. Business Strategies and Development
  • 9.5.3. Exact Sciences Corporation
    • 9.5.3.1. Company Overview
    • 9.5.3.2. Product Portfolio
    • 9.5.3.3. Financial Overview
    • 9.5.3.4. Business Strategies and Development
  • 9.5.4. Foundation Medicine
    • 9.5.4.1. Company Overview
    • 9.5.4.2. Product Portfolio
    • 9.5.4.3. Financial Overview
    • 9.5.4.4. Business Strategies and Development
  • 9.5.5. AnchorDx
    • 9.5.5.1. Company Overview
    • 9.5.5.2. Product Portfolio
    • 9.5.5.3. Financial Overview
    • 9.5.5.4. Business Strategies and Development
  • 9.5.6. Guardant Health, Inc.
    • 9.5.6.1. Company Overview
    • 9.5.6.2. Product Portfolio
    • 9.5.6.3. Financial Overview
    • 9.5.6.4. Business Strategies and Development
  • 9.5.7. Burning Rock Biotech Limited
    • 9.5.7.1. Company Overview
    • 9.5.7.2. Product Portfolio
    • 9.5.7.3. Financial Overview
    • 9.5.7.4. Business Strategies and Development
  • 9.5.8. GENECAST
    • 9.5.8.1. Company Overview
    • 9.5.8.2. Product Portfolio
    • 9.5.8.3. Financial Overview
    • 9.5.8.4. Business Strategies and Development
  • 9.5.9. Laboratory for Advanced Medicine, Inc
    • 9.5.9.1. Company Overview
    • 9.5.9.2. Product Portfolio
    • 9.5.9.3. Business Strategies and Development
  • 9.5.10. Singlera Genomics Inc
    • 9.5.10.1. Company Overview
    • 9.5.10.2. Product Portfolio
    • 9.5.10.3. Financial Overview
    • 9.5.10.4. Business Strategies and Development
  • 9.5.11. Elypta
    • 9.5.11.1. Company Overview
    • 9.5.11.2. Product Portfolio
    • 9.5.11.3. Financial Overview
    • 9.5.11.4. Business Strategies and Development
  • 9.5.12. Prenetics Global Limited (Prenetics)
    • 9.5.12.1. Company Overview
    • 9.5.12.2. Product Portfolio
    • 9.5.12.3. Financial Overview
    • 9.5.12.4. Business Strategies and Development
  • 9.5.13. Oncocyte Corporation
    • 9.5.13.1. Company Overview
    • 9.5.13.2. Product Portfolio
    • 9.5.13.3. Financial Overview
    • 9.5.13.4. Business Strategies and Development
  • 9.5.14. Micronoma Inc
    • 9.5.14.1. Company Overview
    • 9.5.14.2. Product Portfolio
    • 9.5.14.3. Financial Overview
    • 9.5.14.4. Business Strategies and Development
  • 9.5.15. EarlyDiagnostics, Inc
    • 9.5.15.1. Company Overview
    • 9.5.15.2. Product Portfolio
    • 9.5.15.3. Financial Overview
    • 9.5.15.4. Business Strategies and Development

10. Appendix

• 10.1. Research Methodology
• 10.2. Report Assumptions
• 10.3. Acronyms and Abbreviations

관련자료